133 related articles for article (PubMed ID: 16889077)
1. Microemulsions with timolol as potential eye drops.
Malina I; Radomska-Soukharev A
Pharmazie; 2006 Jul; 61(7):650-1. PubMed ID: 16889077
[TBL] [Abstract][Full Text] [Related]
2. Timolol transport from microemulsions trapped in HEMA gels.
Li CC; Abrahamson M; Kapoor Y; Chauhan A
J Colloid Interface Sci; 2007 Nov; 315(1):297-306. PubMed ID: 17673246
[TBL] [Abstract][Full Text] [Related]
3. Development of O/W nanoemulsions for ophthalmic administration of timolol.
Gallarate M; Chirio D; Bussano R; Peira E; Battaglia L; Baratta F; Trotta M
Int J Pharm; 2013 Jan; 440(2):126-34. PubMed ID: 23078859
[TBL] [Abstract][Full Text] [Related]
4. Microemulsions as potential ocular drug delivery systems: phase diagrams and physical properties depending on ingredients.
Radomska-Soukharev A; Wojciechowska J
Acta Pol Pharm; 2005; 62(6):465-71. PubMed ID: 16583987
[TBL] [Abstract][Full Text] [Related]
5. Stability of cefuroxime in 1% and 5% buffered eye drops determined with HPLC method.
Kodym A; Wiśniewski A; Knioła D; Olejniczak M
Acta Pol Pharm; 2011; 68(4):555-64. PubMed ID: 21796938
[TBL] [Abstract][Full Text] [Related]
6. The use of some ingredients for microemulsion preparation containing retinol and its esters.
Radomska A; Dobrucki R
Int J Pharm; 2000 Mar; 196(2):131-4. PubMed ID: 10699703
[TBL] [Abstract][Full Text] [Related]
7. Technology of eye drops containing metronidazole.
Kodym A; Kaczyńska-Dyba E; Kubiak B; Kukuła H
Acta Pol Pharm; 2011; 68(1):109-14. PubMed ID: 21485708
[TBL] [Abstract][Full Text] [Related]
8. Formulation of Carbopol 940 ophthalmic vehicles, and in vitro evaluation of the influence of simulated lacrimal fluid on their physico-chemical properties.
Unlü N; Ludwig A; van Ooteghem M; Hincal AA
Pharmazie; 1991 Nov; 46(11):784-8. PubMed ID: 1811229
[TBL] [Abstract][Full Text] [Related]
9. Physicochemical stability of a new topical timolol 0.5% gel formulation for the treatment of infant hemangioma.
Merino-Bohórquez V; Casas M; Caracuel F; Cameán M; Fernández-Anguita MJ; Ramírez-Soto G; Lucero MJ
Pharm Dev Technol; 2015; 20(5):562-9. PubMed ID: 25047057
[TBL] [Abstract][Full Text] [Related]
10. Physicochemical and microbiological properties of eye drops containing cefuroxime.
Kodym A; Zawisza T; Taberska J; Kukuła H
Acta Pol Pharm; 2006; 63(4):293-9. PubMed ID: 17203867
[TBL] [Abstract][Full Text] [Related]
11. Stability of cefepime in aqueous eye drops.
Kodym A; Pawłowska M; Rumiński JK; Bartosińska A; Kieliba A
Pharmazie; 2011 Jan; 66(1):17-23. PubMed ID: 21391430
[TBL] [Abstract][Full Text] [Related]
12. Formulation and in vitro evaluation of cysteamine hydrochloride viscous solutions for the treatment of corneal cystinosis.
Bozdağ S; Gümüş K; Gümüş O; Unlü N
Eur J Pharm Biopharm; 2008 Sep; 70(1):260-9. PubMed ID: 18590953
[TBL] [Abstract][Full Text] [Related]
13. Influence of additives and storage temperature on physicochemical and microbiological properties of eye drops containing ceftazidime.
Kodym A; Zawisza T; Napierała B; Kukuła H
Acta Pol Pharm; 2006; 63(6):507-13. PubMed ID: 17438868
[TBL] [Abstract][Full Text] [Related]
14. Influence of additives and storage temperature on physicochemical and microbiological properties of eye drops containing cefazolin.
Kodym A; Zawisza T; Buźka K; Kukuła H
Acta Pol Pharm; 2006; 63(3):225-34. PubMed ID: 20085229
[TBL] [Abstract][Full Text] [Related]
15. Technology of eye drops containing aloe (Aloe arborescens Mill.--Liliaceae) and eye drops containing both aloe and neomycin sulphate.
Kodym A; Marcinkowski A; Kukuła H
Acta Pol Pharm; 2003; 60(1):31-9. PubMed ID: 12848365
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction.
Edeki TI; He H; Wood AJ
JAMA; 1995 Nov 22-29; 274(20):1611-3. PubMed ID: 7474246
[TBL] [Abstract][Full Text] [Related]
17. Physicochemical and pharmacological investigation of water/oil microemulsion of non-selective beta blocker for treatment of glaucoma.
Hegde RR; Bhattacharya SS; Verma A; Ghosh A
Curr Eye Res; 2014 Feb; 39(2):155-63. PubMed ID: 24073659
[TBL] [Abstract][Full Text] [Related]
18. Tear fluid-eye drops compatibility assessment using surface tension.
Hotujac Grgurević M; Juretić M; Hafner A; Lovrić J; Pepić I
Drug Dev Ind Pharm; 2017 Feb; 43(2):275-282. PubMed ID: 27645109
[TBL] [Abstract][Full Text] [Related]
19. Generic versus brand-name North American topical glaucoma drops.
Mammo ZN; Flanagan JG; James DF; Trope GE
Can J Ophthalmol; 2012 Feb; 47(1):55-61. PubMed ID: 22333853
[TBL] [Abstract][Full Text] [Related]
20. Physical and chemical properties and stability of sodium cefazolin in buffered eye drops determined with HPLC method.
Kodym A; Bilski P; Domańska A; Hełminiak Ł; Jabłońska M; Jachymska A
Acta Pol Pharm; 2012; 69(1):95-105. PubMed ID: 22574512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
